Patricia Allen Acquires 18,500 Shares of ZBIO
Insider buying continues at ZBIO with Patricia Allen and others acquiring shares.
Key Points
- On June 15, 2026, Patricia Allen purchased 18,500 shares of ZBIO, joining other insiders in buying the stock.
- Shares of ZBIO traded around $18.58, with institutional investors like FMR LLC and Polar Capital Holdings PLC adjusting their positions.
- Analysts have mixed views on ZBIO, with Morgan Stanley maintaining a hold rating and Citigroup a buy rating.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Patricia Allen, an insider at ZBIO, bought 18,500 shares on June 15, 2026. This purchase is part of a larger pattern of insider buying, as several other insiders also acquired shares on the same day.
Other Institutional Activity in ZBIO
FMR LLC increased its holdings by 1,377,745 shares, ending with 9,082,000 shares valued at approximately $177.6 million. Polar Capital Holdings PLC made a notable move, adding 1,490,835 shares to reach a total of 2,548,444 shares worth about $49.8 million. Meanwhile, NEA Management Company, LLC grew its position by 500,000 shares, bringing its total to 4,023,219 shares valued at roughly $78.7 million.
Zenas BioPharma, Inc. Stock Down 40.6%
Shares of ZBIO traded near $18.58. While specific financial metrics like market cap and P/E ratio aren't available, the stock's performance is closely watched by institutional investors and analysts.
Insider Buying and Selling at Zenas BioPharma, Inc.
On June 15, 2026, multiple insiders purchased shares of ZBIO. James Boylan, Patricia Allen, and Jason Raleigh Nunn each acquired 18,500 shares. Joseph Farmer, President and COO, bought 175,000 shares, while Lisa Von Moltke, Head of Research and Development and Chief Medical Officer, purchased 150,000 shares. Jennifer Fox, Chief Business Officer and CFO, acquired 125,000 shares. These transactions were not part of a pre-arranged trading plan.
Analysts Set New Price Targets
On May 14, 2026, Morgan Stanley maintained a hold rating with a $22 price target. Earlier, on March 17, 2026, Citigroup and Guggenheim both maintained buy ratings, with targets of $41 and $55, respectively. HC Wainwright & Co. reiterated a buy rating with a $44 target on February 10, 2026.
Bottom Line
Insider buying at ZBIO suggests confidence among company executives, though the transactions' timing may not reflect current market conditions. Institutional investors and analysts show varied opinions, indicating a complex investment landscape. As always, it's important to consider multiple factors when evaluating a stock's potential.
Get Zenas BioPharma, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ZBIO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.